Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $18.54 which represents a decrease of $-2.99 or -13.89% from the prior close of $21.53. The stock opened at $19.18 and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Israeli generics giant Teva Pharmaceutical Industries today reported results for the year and the quarter ended December 31, ...